Abstract
Nerve growth factor (NGF) administration to athymic mice with transplanted human bromocriptine-resistant prolactinoma, results in the expression of dopamine D-2 receptors in the tumour and restores sensitivity to subsequent treatment with bromocriptine, which then produces normalisation of plasma prolactin and tumour regression. Sequential administration of NGF and bromocriptine thus may be a promising therapy for patients refractory to bromocriptine.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Missale, C., Losa, M., Boroni, F. et al. Nerve growth factor and bromocriptine: a sequential therapy for human bromocriptine-resistant prolactinomas. Br J Cancer 72, 1397–1399 (1995). https://doi.org/10.1038/bjc.1995.520
Issue Date:
DOI: https://doi.org/10.1038/bjc.1995.520
- Springer Nature Limited
This article is cited by
-
Pharmacologic Resistance in Prolactinoma Patients
Pituitary (2005)
-
Brain sites of movement disorder: Genetic and environmental agents in neurodevelopmental perturbations
Neurotoxicity Research (2003)
-
Neurotrophic factors for the investigation and treatment of movement disorders
Neurotoxicity Research (2003)
-
Growth factors in the pathogenesis of prolactin-secreting tumors
Journal of Endocrinological Investigation (1998)